Compare SVM & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVM | INVA |
|---|---|---|
| Founded | N/A | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2005 | 2000 |
| Metric | SVM | INVA |
|---|---|---|
| Price | $9.53 | $20.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $10.50 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 2.2M | 625.5K |
| Earning Date | 05-25-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | N/A | ★ 816.67 |
| EPS | N/A | ★ 2.22 |
| Revenue | N/A | ★ $217,217,000.00 |
| Revenue This Year | $36.87 | $8.95 |
| Revenue Next Year | $35.34 | $12.65 |
| P/E Ratio | ★ N/A | $9.45 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $4.29 | $16.52 |
| 52 Week High | $15.77 | $25.15 |
| Indicator | SVM | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 45.74 | 36.46 |
| Support Level | $8.68 | $19.15 |
| Resistance Level | $10.19 | $22.86 |
| Average True Range (ATR) | 0.44 | 0.46 |
| MACD | 0.09 | -0.07 |
| Stochastic Oscillator | 56.21 | 5.88 |
Silvercorp Metals Inc is engaged in the acquisition, exploration, development, and mining of mineral properties. The Company's producing mines are located in China, and current exploration and development projects are located in China, Ecuador and Kyrgyz Republic. The company operates in single segment. The Company mainly produces and sells silver, lead, zinc, gold and other metals. The company's producing projects are Ying Mining District, GC Mine; construction projects are El Domo; permitting project is BYP Mine; development project includes Condor, Tulkubash/Kyzyltash.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.